您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > 17-Hydroxyprogesterone
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
17-Hydroxyprogesterone
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
17-Hydroxyprogesterone图片
CAS NO:68-96-2
规格:98%
分子量:330.46
包装与价格:
包装价格(元)
50mg电议
200mg电议

产品介绍
endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones
CAS:68-96-2
分子式:C21H30O3
分子量:330.46
纯度:98%
存储:Store at -20°C

Background:

17-Hydroxyprogesterone, an endogenous progestogen and chemical intermediate in the biosynthesis of other steroid hormones, is also the parent compound of various progestins derivatives.


In vitro: 17-Hydroxyprogesterone was found to be an agonist of the progesterone receptor (PR), which was similarly to progesterone. In addition, 17-hydroxyprogesterone was also an antagonist of the mineralocorticoid receptor (MR) as well as a partial agonist of the glucocorticoid receptor (GR), with very low potency (EC50>100-fold less relative to cortisol), which was also similarly to progesterone [1].


In vivo: Findings from a previous rat in vivo study demonstrated that even if modest, lowering blood pressure with 17-hydroxyprogesterone could be a viable treatment selection for blocking inflammation and uterine artery vasoconstriction, whereas improving litter size [2].


Clinical trial: Clinically, 17-hydroxyprogesterone has been evaluated in newborn screening programs as the biomarker to detect the rare but potentially fatal inherited disease, such as congenital adrenal hyperplasia. Results showed that the respiratory distress syndrome was related with higher 17-hydroxyprogesterone level. In addition, higher 17-hydroxyprogesterone and false positives were found to be significantly related with lower gestational age and birth weight, which was the same as that previously reported [3].


参考文献:
[1] Barbara J.  Attardi, et al. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate (17-OHPC), and related progestins. Am J Obstet Gynecol. 2007 Dec; 197(6): 599.e1–599.e7.
[2] Lorena M.  Amaral, et al. 17- hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the Rupp rat model. Hypertension. 2015 Jan; 65(1): 225–231.
[3] Ryckman KK,Cook DE,Berberich SL,Shchelochkov OA,Berends SK,Busch T,Dagle JM,Murray JC.  Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns. J Pediatr Endocrinol Metab. 2012;25(3-4):301-5.